ArticlePLoS pathogens2021
Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19.
Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- A biosafe mouse model for SARS-CoV-2 infection that more realistically simulates COVID-19 symptoms.Signal transduction and targeted therapy · 2026Article
- Animal models in human surgery and implant innovation: ethical considerations and scientific advancements.Annals of medicine and surgery (2012) · 2025Article
- Review
- CD4Science advances · 2024Article
- An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo.Virologica Sinica · 2024Article
- Establishment and characterization of an hFrontiers in immunology · 2024Article
- AAV-based vectors for human diseases modeling in laboratory animals.Frontiers in medicine · 2024Review
- A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.Emerging microbes & infections · 2023Article
- Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Inhibition of SARS-CoV-2-mediated thromboinflammation by CLEC2.Fc.EMBO molecular medicine · 2023Article
- Optimization and Improvement of qPCR Detection Sensitivity of SARS-CoV-2 in Saliva.Microbiology spectrum · 2023Article
- Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion.Journal of medical virology · 2023Article
- A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.Emerging microbes & infections · 2022Article
- Quantitative proteomics and biological activity of extracellular vesicles engineered to express SARS-CoV-2 spike protein.Journal of extracellular biology · 2022Article
- CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation.Journal of biomedical science · 2022Article
- A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.Journal of biomedical science · 2022Article
- Review
- Furin and TMPRSS2 Resistant Spike Induces Robust Humoral and Cellular Immunity Against SARS-CoV-2 Lethal Infection.Frontiers in immunology · 2022Article
- Generation of SARS-CoV-2 Mouse Model by Transient Expression of the HumanMolecular biology · 2022Article
- Natural Transmission and Experimental Models of SARS CoV-2 Infection in Animals.Comparative medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the pandemic of COVID-19 has intensely struck human society, small animal model for this infectious disease is in urgent need for basic and pharmaceutical research. Although several COVID-19 animal models have been identified, many of them show either minimal or inadequate pathophysiology after SARS-CoV-2 challenge. Here, we describe a new and versatile strategy to rapidly establish a mouse model for emerging infectious diseases in one month by multi-route, multi-serotype transduction with recombinant adeno-associated virus (AAV) vectors expressing viral receptor. In this study, the proposed approach enables profound and enduring systemic expression of SARS-CoV-2-receptor hACE2 in wild-type mice and renders them vulnerable to SARS-CoV-2 infection. Upon virus challenge, generated AAV/hACE2 mice showed pathophysiology closely mimicking the patients with severe COVID-19. The efficacy of a novel therapeutic antibody cocktail RBD-chAbs for COVID-19 was tested and confirmed by using this AAV/hACE2 mouse model, further demonstrating its successful application in drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.